ETF Building Blocks Channel Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Channel Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
Innovative ETFs Channel Moderna Vaccine Is Granted Authorization in Australia By Max ChenAugust 9, 2021
Beyond Basic Beta Channel Mostly Sanguine Regulatory Outlook for Biotech, Healthcare Names By Tom LydonJuly 30, 2021
ETF Building Blocks Channel Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
Beyond Basic Beta Channel Changing FDA Regulatory Environment Could Bolster Biotech, ‘BBH’ By Tom LydonJuly 1, 2021
ETF Building Blocks Channel Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
Innovative ETFs Channel Will Biotech ETFs Benefit from Biogen’s New Alzheimer’s Drug? By Ian YoungJune 9, 2021
ETF Building Blocks Channel As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
Equity ETF Channel Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause By Ian YoungApril 13, 2021
Beyond Basic Beta Channel Biotech Shined with Vaccines. It Can Do It Again with ‘BBH’ By Ben HernandezMarch 3, 2021
Innovative ETFs Channel Illumina Earnings, Forward Guidance Strengthen Biotech ETFs By Max ChenFebruary 12, 2021
Beyond Basic Beta Channel IPOs Are Back. Get In On the Action with the BBH ETF By Ben HernandezFebruary 9, 2021
Innovative ETFs Channel Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug By Max ChenJanuary 29, 2021
ETF Building Blocks Channel ALPS ‘SBIO’ ETF: Trial Progress Meets Investing Success By Tom LydonJanuary 25, 2021
ETF Building Blocks Channel Don’t Miss Out on Rampant Biotech Mergers with the SBIO ETF By Tom LydonJanuary 13, 2021